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Richter syndrome (RS) is associated with chemotherapy resistance and a
poor historical median overall survival (OS) of 8–10 months. We con-
ducted a phase II trial of standard CHOP-21 (cyclophosphamide, doxoru-
bicin, vincristine, prednisolone every 21 d) with ofatumumab induction
(Cycle 1: 300 mg day 1, 1000 mg day 8, 1000 mg day 15; Cycles 2–6:
1000 mg day 1) (CHOP-O) followed by 12 months ofatumumab mainte-
nance (1000 mg given 8-weekly for up to six cycles). Forty-three patients
were recruited of whom 37 were evaluable. Seventy-three per cent were
aged >60 years. Over half of the patients received a fludarabine and
cyclophosphamide-based regimen as prior CLL treatment. The overall
response rate was 46% (complete response 27%, partial response 19%) at
six cycles. The median progression-free survival was 62 months (95% con-
fidence interval [CI] 49–140 months) and median OS was 114 months
(95% CI 64–256 months). Treatment-na€ıve and TP53-intact patients had
improved outcomes. Fifteen episodes of neutropenic fever and 46 non-neu-
tropenic infections were observed. There were no treatment-related deaths.
Seven patients received platinum-containing salvage at progression, with
only one patient obtaining an adequate response to proceed to allogeneic
transplantation. CHOP-O with ofatumumab maintenance provides mini-
mal benefit beyond CHOP plus rutuximab. Standard immunochemother-
apy for RS remains wholly inadequate for unselected RS. Multinational
trials incorporating novel agents are urgently needed.
Keywords: Ofatumumab, CHOP, TP53, Richter syndrome, Chronic
lymphocytic leukaemia.
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B-cell chronic lymphocytic leukaemia (CLL) is the most
common indolent chronic lymphoproliferative disease. 2–
15% of patients (Rossi et al, 2011; 2008; Tsimberidou et al,
2006) transform to an invariably aggressive, chemo-resistant
high-grade non-Hodgkin lymphoma (NHL) (Morton et al,
2006). Broadly, NHL represents the fifth most common
cancer worldwide and its incidence continues to increase
(Morton et al, 2006). Richter syndrome (RS) is a rare
complication of CLL, characterized by rapidly growing and/
or asymmetrical lymphadenopathy or extranodal fluo-
rodeoxyglucose ([18F]DG) positron-emission-tomography
(PET) computerized tomography (CT)-avid masses, new B
symptoms, a rapidly rising lactate dehydrogenase (LDH) or
new hypercalcaemia in a patient with known CLL. Most RS
represent transformation to a clonally-related activated B-cell
type (ABC) diffuse large B-cell lymphoma (DLBCL) (90–
95%) with a small proportion transforming to Hodgkin lym-
phoma (Bockorny et al, 2012). The long-term overall survival
(OS) of de novo DLBCL following the introduction of the
anti-CD20 monoclonal antibody rituximab in those fit for an
anthracycline-based regimen, typically CHOP (cyclophos-
phamide, doxorubicin, vincristine, prednisolone) approaches
70% (Coiffier et al, 2002).
RS can present in either heavily pre-treated, immunosup-
pressed patients or in untreated CLL patients (Parikh et al,
2013). Patients typically present with a rapidly worsening
performance status and often possess therapy-limiting
co-morbidities. No randomized trials have been published.
Alkylator, anthracycline, platinum and purine analogue
chemotherapy have been investigated in RS. Rituximab (R)-
CHOP (Coiffier et al, 2002), R-hyper-CVXD-MA (fraction-
ated cyclophosphamide, vincristine, liposomal daunorubicin,
dexamethasone plus rituximab, alternating with methotrexate
and cytarabine with rituximab) (Tsimberidou et al, 2003),
hyper-CVXD alone (Dabaja et al, 2001), FACPGM (fludara-
bine, cytarabine, cyclophosphamide, cisplatin and GM-CSF)
(Tsimberidou et al, 2002), OFAR1 and OFAR2 (oxaliplatin,
fludarabine, cytarabine, rituximab and pegfilgrastim) (Tsim-
beridou et al, 2008, 2013) regimens have been used. The best
response rates are 41% with hyper-CVXD and R-hyper-
CVXD-MA and 50% with OFAR1, although responses are
short-lived. These regimens are toxic and inappropriate for
many elderly patients with RS. The median survival of 8–
10 months (Tsimberidou et al, 2006; Tadmor et al, 2014)
from diagnosis has not been bettered in the literature
although a recent small cohort of 15 RS patients treated with
R-CHOP displayed an overall response rate (ORR) of 67%
and a median OS of 21 months (Langerbeins et al, 2014).
Autologous and allogeneic stem cell transplantation (SCT)
are typically reserved for exceptional patients aged less than
65 years with good performance status and chemo-sensitive
disease (Parikh et al, 2013).
Ofatumumab is a fully human monoclonal IgG anti-CD20
antibody that specifically targets a unique membrane-proxi-
mal epitope of CD20 on B-cells with increased affinity and a
longer dissociation time compared to rituximab. This mecha-
nism is thought to improve complement-mediated cellular
cytotoxicity (Teeling et al, 2006; Barth et al, 2012). Ofatu-
mumab has the potential to induce B-cell apoptosis indepen-
dent of TP53 (p53). At the time, its efficacy in CLL
refractory to fludarabine and alemtuzumab (a group that
commonly possess TP53-disruption (Wierda et al, 2010) led
to its accelerated US Food and Drug Administration (FDA)
approval in this indication. In view of the high incidence of
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TP53-disruption in DLBCL-RS (Chigrinova et al, 2013) and
the well documented risk of early relapse, ofatumumab
induction (alongside CHOP) and maintenance represented a
biologically sound treatment rationale for patients with RS.
Patients and Methods
Study design
The ‘CHOP-OR’ trial was a single arm, multi-centre, non-
randomized phase II National Cancer Research Institute
(NCRI) feasibility study in patients with newly diagnosed
RS, recruiting from 10 UK centres from April 2011 to
December 2014. Forty-three patients were enrolled of whom
37 were ultimately evaluable for objective overall response
within the trial. Eligible patients received CHOP-O for six
cycles, followed by six cycles of ofatumumab maintenance
every eight weeks. The primary objective of the CHOP-OR
study was to determine objective response to CHOP-O at
week 20 as measured from start of treatment according to
the Revised Response Criteria for Malignant Lymphoma
(Cheson et al, 2007). Response to treatment and disease
progression was assessed by the local investigator. Secondary
objectives included assessing the feasibility of recruitment,
progression-free survival (PFS) and OS, the clinical benefit
and changes in patient-reported outcomes (PROs), safety
and tolerability. Simon’s minimax two-stage design was
implemented to calculate the required sample size (n = 35)
to identify a desired response of the trial drug of 47% with
a power of 80% and significance of 20%. For a detailed
description of the study design, patient selection, statistical
design, interventions and outcome measures, the reader is
directed to the open access protocol manuscript (Eyre et al,
2015).
Exploratory outcome measures
Given the relative lack of prospective clinical trials performed
in RS, there have been few attempts to use clinical features
to assess prognostic factors. Two scoring systems have been
published. Parikh et al (2013) validated a clinical scoring sys-
tem in a retrospective dataset developed by Tsimberidou et al
(2006). Adverse risk factors within the scoring system are: 1.
Eastern Cooperative Oncology Group (ECOG) performance
status (PS) >1, 2. LDH ≥15 the upper limit of normal, 3.
Platelet count <100 9 109/l, 4. Tumour bulk >5 cm, 5. >1
previous lines of chemotherapy for underlying CLL. Patients
with a score of 4–5 have a median survival of 01 years, com-
pared to those with a score of 0–1 who have a median sur-
vival of 11 years. A second scoring system by Rossi et al
(2011) described three factors: 1. ECOG PS >1, 2. Less than
complete response (CR) to induction immuno-chemother-
apy, 3. Presence of TP53 disruption (deletion or mutation).
In this large retrospective analysis, patients with no risk fac-
tors had a 5-year survival of 70%. Those with an ECOG PS
>1 had a survival of 07 years and those with a performance
status ≤1 with TP53 disruption or less than CR after induc-
tion had a median survival of 2 years (Rossi et al, 2011). We
aimed to further validate both these scoring systems within
the CHOP-OR trial.
Immunohistochemistry (IHC), In-situ hybridization
(ISH) and Fluorescent In-Situ Hybridization (FISH)
Using the Hans algorithm (Hans et al, 2004), the cell of ori-
gin was determined by IHC in all patients where feasible,
using antibodies from either Novocastra-Leica, Newcastle UK
or Dako, Ely, UK on a Bond MaxTM immunostaining
machine (Novocastra-Leica). In addition, diagnostic forma-
lin-fixed paraffin embedded (FFPE) tissue was analysed for
Epstein–Barr virus (EBV) expression by ISH, for EBV-
encoded RNA (EBER, Novocastra-Leica) or latent membrane
protein-1 (LMP-1, Novocastra-Leica) by IHC both on a
Bond MaxTM immunostaining machine (Novocastra-Leica).
Data on c-Myelocytomatosis (MYC, Novocastra-Leica)
tumour expression by IHC (percentage) and/or FISH (Vysis
LSI MYC dual colour break-apart rearrangement probes
(Abbott Molecular, Maidenhead UK)) was also collected. The
median percentage MYC expression was correlated with clin-
ical outcome in a similar fashion to Green et al (2012) using
a median score cut off.
TP53 disruption
Patients were considered to have TP53 disruption if either a
TP53 deletion or mutation (by FISH or next generation
sequencing [NGS] DNA analysis) was found in the CLL
clone and/or the DLBCL tumour FFPE tissue. TP53 mutation
status was determined using a TruSeq Custom Amplicon
panel (TSCA, Illumina, San Diego, CA, USA) targeting muta-
tional hotspots. Libraries were created from 250 ng of DNA,
before undergoing 2 9 150 bp paired-end sequencing on the
MiSeq platform (Illumina). Initial alignment and variant call-
ing analysis was performed with the TSCA Workflow of
MiSeq Reporter v.24 (Illumina) using the default settings.
A second alignment followed by variant calling using the
Stampy v.1022 (http://www.well.ox.ac.uk/project-stampy)
and Platypus v.051 (http://www.well.ox.ac.uk/platypus) soft-
ware to specifically identify additional insertions and dele-
tions (InDels) not detected with MiSeq Reporter.
IGHV gene mutational analysis
IGHV gene mutational analysis was performed as previously
described (Campbell et al, 1992), and the sequences were
aligned with those in the international ImMunoGeneTics
(IMGT) information system database (http://imgt.cines.fr).
Sequences with less than 2% deviation from any germline
IGHV sequence were considered unmutated (Hamblin et al,
1999).
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All available diagnostic samples underwent central
histopathology review by two expert haemato-pathologists
who reviewed the cases independently and then together.
FDG-PET
FDG PET-CT has been shown to be useful in differentiating
accelerated, ‘aggressive’ CLL and RS (Bruzzi et al, 2006; Fal-
chi et al, 2014; Papajık et al, 2014). Although FDG PET-CT
was not mandated prior to CHOP-O, a number of centres
performed a prior PET-CT with the aim to accurately stage
patients and to direct a diagnostic biopsy. As such, data on
whether a PET-CT was performed, the disease stage and the
maximum standardized uptake value (SUVmax) were also
collected.
Ethics and Authors Contributions
The institutional review board or ethics committee of each
participating institution approved the study protocol, and
each patient provided written informed consent before enrol-
ment. The trial sponsor was responsible for data gathering
and pharmacovigilance, and to share safety data throughout
the study with the corresponding author and an independent
trial safety committee. The sponsor and the authors were
responsible for data analysis and interpretation. The corre-
sponding author had full access to all the data in the study
and all authors approved the manuscript for submission for
publication. The corresponding author had final responsibility
for the decision to submit the manuscript for full publication.
Results
The CHOP-OR trial was the first UK-wide prospective study
in RS and is the largest prospective study performed to date
in RS. Between April 2011 and December 2014, 43 patients
in total fulfilled eligibility criteria for the trial. Of those, 37
patients were evaluable according to pre-defined criteria
(Fig 1; Supplemental Fig 1).
All non-evaluable patients were defined by failure to com-
plete one full cycle of CHOP-O on trial. Table I describes
the baseline demographics, clinical characteristics and prior
treatments for the 37 evaluable patients. Categorical variables
are presented as n (%); continuous variables are presented as
mean (range, standard deviation [SD]). Seventy-three per
cent of patients were aged over 60 years, and 70% were male
gender. Patients received a median of 1 prior therapy (range
0–4) for CLL prior to high-grade transformation with over
half of pre-treated patients having received a fludarabine and
cyclophosphamide based regimen. Forty-six per cent of
patients were CLL treatment-na€ıve at transformation. TP53
disruption was noted in 43% of patients either at or already
prior to transformation.
The ORR (CR plus partial response [PR]) to CHOP-O
induction was 46% (95% CI 297–622%; CR 27%, PR 19%)
at the end of six cycles of induction. Eighteen patients started
maintenance, which nine completed. At the time of data cen-
soring, three were receiving ongoing maintenance. The med-
ian PFS was 62 months (95% CI 49–140 months), with no
convincingly clear plateau on the PFS or OS curves (Fig 2A,
2B). The median OS was 114 months (95% CI 64–
256 months), consistent with outcomes described in the lit-
erature using R-CHOP and platinum-based regimens (Coif-
fier et al, 2002; Tsimberidou et al, 2008, 2013; Parikh et al,
2013; Langerbeins et al, 2014). Patients received a median
number of six courses of CHOP-O (interquartile range 4–6).
The reasons for discontinuation of therapy of those evaluable
on the trial were: treatment failure (n = 15), treatment toxic-
ity or adverse events (n = 5), clinician or patient decision
(n = 3) and death (n = 2).
Baseline FDG PET-CT was performed in 42% of enrolled
patients, with no clear change of scanning frequency occur-
ring over the recruitment period. The mean SUVmax was
208 (range in patients with measurable disease 585–694).
The sites of SUVmax and the pattern of baseline PET CT
usage are described in Supplemental Figure 2. One patient
who received a PET-CT had a central histopathology review
consistent with accelerated CLL rather than RS. The SUVmax
in that patient was 103. All other patients who received a
PET-CT, including the other three patients with SUVmax
<10, were assessed by central histopathology as RS.
EBV expression was examined by ISH, IHC or both in 29
of the 37 eligible patients. EBV expression was found in only
two patients, where widespread LMP-1 expression was noted.
Neither of these two patients had received prior fludarabine-
based CLL therapy and one was treatment-na€ıve. TP53 status
was assessed in 36 of 37 patients. TP53 was disrupted in 43%
of cases by FISH or sequencing analysis. Cell of origin was
evaluated in 33 of 37 cases by the Hans algorithm (Hans
et al, 2004). ABC type DLBCL (25 of 33 evaluable; 76%) was
most commonly seen. Eight patients had germinal-centre
type DLBCL and 4 patients had inadequate tissue for assess-
ment. MYC expression was assessed in 30 patients by IHC
(including two by FISH in addition) and one separate case
by FISH alone. All 3 cases were negative by FISH. The med-
ian percentage expression was 20% (range 0–70%; mean
21%). This median percentage MYC expression was then
used to assess correlations with clinical outcome (<20% ver-
sus ≥20%).
The subgroup analysis (Fig 3C-D) aimed to assess the rel-
ative prognostic value of the Rossi score, the Tsimberidou
score, and the International Prognostic Score (Supplemental
Fig 3A). Patients who were treatment-na€ıve had a signifi-
cantly superior survival than patients who had received at
least one prior line of therapy for the underling CLL (Fig 3A;
P = 0007). Five durable remissions of 18 months or more
were noted in the treatment-na€ıve cohort (Fig 3A). The ORR
rate of treatment-na€ıve and pre-treated patients was 529%
and 400% respectively. Patients with TP53 disruption had a
significantly inferior survival than those that did not (Fig 3B;
T. A. Eyre et al
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P = 0044). The cell of origin (supplemental Fig 3B) and
MYC status (<20% verses ≥20%) (supplemental Fig 3C) of
the DLBCL did not influence survival. The data available for
IGHV clonality was limited by tissue availability. Of the 20
patients assessable by IGHV clonality studies, 17 were evalu-
able within the trial for outcome data. Of those 17, only 1
patient had DLBCL that was clonally unrelated to their
underlying CLL. This patient progressed post-Cycle 5 after a
PR at Cycle 4. Six patients had not relapsed at the time of
data censoring. Of these 6, the majority (n = 5) had both an
excellent ECOG PS (0–1) at baseline, and 5 of 6 had no
TP53 disruption. Key baseline characteristics were assessed
for their influence on the ORR as the primary outcome mea-
sure in a forest plot (Fig 4). There were no clear subgroups
that had notably superior responses to CHOP-O induction
at the end of Cycle 6.
A retrospective central histopathology review was per-
formed by two expert haematopathologists. Forty of the 43
cases were available for central review, of which 175%
(n = 7) were considered to have features consistent with CLL
or accelerated/aggressive CLL and 825% (n = 33) RS (1
Hodgkin-type, 32 DLBCL-type). No clear difference in sur-
vival outcome in those evaluable could be demonstrated
according to the histopathology subgroup as defined by cen-
tral review (Supplemental Fig 3D). All patients were included
within the analysis independent of central review status.
When patients deemed to have aggressive CLL by central
review were excluded from analysis, the survival outcomes
were unchanged across all subgroups.
Safety
As predicted for this patient group, CHOP-O caused a signifi-
cant number of adverse events (AEs; n = 85) and serious
adverse events (SAEs; n = 50). None of these were unexpected.
Table II displays a summary of the key grade 3–4 adverse
Fig 1. Consort diagram AE, adverse event;
SAE, serious adverse event.
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Table I. Baseline Characteristics
Baseline characteristic
All evaluable
patients (N = 37)
n (%)
Age, years; mean (range, SD) 662 (43–90, 113)
<60 years 10 (27%)
≥60 years 27 (73%)
Gender
Male 26 (70%)
Female 11 (30%)
ECOG performance status
0 17 (46%)
1 12 (32%)
2 4 (11%)
3 4 (11%)
No. of extranodal sites
0 19 (51%)
1 13 (35%)
>1 5 (14%)
Ann Arbour staging
I 6 (16%)
II 6 (16%)
III 15 (41%)
IV 9 (24%)
Not assessed/documented 1 (3%)
Rai staging
0 11 (30%)
I 12 (32%)
II 8 (22%)
III 3 (8%)
IV 2 (5%)
Not assessed/documented 1 (3%)
Binet staging
A 19 (51%)
B 12 (32%)
C 6 (16%)
B-symptoms history
Yes 22 (59%)
No 15 (41%)
LDH level
<ULN 13 (35%)
>ULN 24 (65%)
LDH > 15 9 ULN 11 (30%)
Platelet count
<100 9 109/l 10 (27%)
≥100 9 109/l 27 (73%)
Beta-2 Microglobulin
<ULN 14 (38%)
>ULN 18 (49%)
Not assessed/documented 5 (14%)
Bulk in lymph node over 5 cm
Yes 18 (49%)
No 19 (51%)
TP53 disruption
Yes 16 (43%)
No 20 (54%)
No data available 1 (3%)
EBV expression
Positive 2 (7%)
Table I. (Continued)
Baseline characteristic
All evaluable
patients (N = 37)
n (%)
Negative 27 (93%)
Not assessed 8
Cell of origin
Activated B cell (ABC) 25 (76%)
Germinal centre (GC) 8 (24%)
Undefined as inadequate tissue 4
MYC expression Median
expression
20%
(range 0–90%)
<20% 12
≥20% 18
FISH only (negative) 1
Not assessed 6
Previous treatments
0 17 (46%)
1 12 (32%)
>1 8 (22%)
Previous B-CLL treatments (Number of
patients who
received
treatment
previously)
Fludarabine + cyclophosphamide + rituximab 12
Fludarabine + cyclophosphamide 8
Chlorambucil  rituximab 5
Alemtuzumab  Steroid (High dose) 4
Rituximab 2
Other 6
Tsimberidou score (Tsimberidou et al, 2006)
0–1 19 (51%)
2–3 17 (46%)
4–5 1 (3%)
Rossi score (Rossi et al, 2011)
Low risk 6 (16%)
Intermediate risk 23 (62%)
High risk 7 (19%)
Data not available 1 (3%)
International prognostic index (IPI) score
Low 0–1 10 (27%)
Low/Intermediate 2 10 (27%)
High/Intermediate 3 9 (24%)
High > 4 7 (19%)
Data not available 1 (3%)
Central histopathology review (all 43 enrolled patients)
Richter (DLBCL type) 33 (825%)
(29 evaluable)
Not Richter (CLL or accelerated CLL) 7 (175%)
(6 evaluable)
Tissue unavailable 3 (2 evaluable)
ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydro-
genase; ULN, upper limit of normal; EBV, Epstein-Barr virus;
DLBCL, diffuse large B cell lymphoma; CLL, chronic lymphocytic
leukaemia; SD, standard deviation.
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events reported across all 43 patients. Fifteen episodes of neu-
tropenic fever were reported and grade 3–4 neutropenia was
noted on 14 occasions. Forty-six additional non-neutropenic
infections were noted, of which 21 were SAEs. A single SAE as
the result of an ofatumumab-induced infusion reaction was
reported. No treatment-related deaths were reported.
Median OS = 11·44 months
(95%CI 6·38-25·64)
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Fig 2. Survival outcomes - A: progression-free survival (PFS). B: overall survival (OS).
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Management at progression and outcome
Seven patients received platinum-containing salvage at pro-
gression, and only a single patient (Patient 2, Table III) had
sufficiently chemo-responsive disease to receive an allogeneic
stem cell transplantation. No patient received an autologous
SCT. The outcome in those considered fit enough for plat-
inum-based salvage chemotherapy at relapse post-CHOP-O
was generally poor.
Discussion
The successful completion of this trial proves the feasibility
of studying novel combinations in a rare disease and shows
the importance of productive national collaboration. This
study achieved a key secondary end point by showing that it
is feasible to study clinico-pathological features of RS and
answers important therapy-based questions in clinical trials.
Although not compared in a prospective randomized clinical
trial, our data shows that CHOP-O does not noticeably
improve response and survival outcomes when judged aside
historical outcomes after R-CHOP in RS (n = 15, ORR 67%,
median PFS = 10 months, OS = 21 months) (Langerbeins
et al, 2014). A recent retrospective series of 46 patients with
newly diagnosed RS (42 of which were DLBCL-subtype) trea-
ted with etoposide, vincristine, cyclophosphamide, doxoru-
bicin and rituximab (EPOCH-R) showed limited efficacy
with poor PFS (median 35 months) and OS (median
59 months) (Rogers et al, 2015). We demonstrate that sur-
vival following relapsed RS is poor. Patients are typically
platinum refractory and survived for a median of just over
2 months after relapse.
Although small numbers limited our subgroup analysis,
our results were consistent with the prior published data of
prognostic scoring systems. Rossi et al (2011) demonstrated
the prognostic impact of TP53 disruption in a retrospective
series of 86 patients. We demonstrate for the first time
within a prospective clinical trial, that patients with RS and
TP53 disruption have an inferior survival to those without
TP53 disruption. The fact that 50% of patients with RS have
TP53 disruption means that novel drugs for this condition
need to act independently of TP53.
We also demonstrate for the first time in a prospective
clinical trial that patients with treatment-na€ıve CLL at the
time of transformation have a superior outcome compared
to those that are previously treated. This is probably related
to immunosuppression, prior myelotoxicity and the selection
and subsequent transformation of immunochemotherapy-
resistant subclones.
Results from PET-CT are consistent with data in the liter-
ature that supports the utility of this imaging to exclude RS
and direct biopsy. A number of studies have shown that
using an SUVmax cut off of 50 could detect DLBCL-type
All patients
Age
< 60 years
≥ 60 years
Rai stage
0 or I
II, III or IV
TP53 disruption?
Yes
No
IPI
0-2
3-5
Tsimberidou score
0-1
2-4
Cell of origin
ABC
GCB
MYC
< 20% expression
≥ 20% expression
Prior treatments
0
≥ 1
Subgroup
46·0 (29·7, 62·2)
40·0 (8·0, 72·0)
48·2 (28·9, 67·4)
56·5 (35·8, 77·2)
30·8 (4·7, 56·9)
31·3 (7·8, 54·7)
55·0 (32·6, 77·4)
55·0 (32·6, 77·4)
31·3 (7·8, 54·7)
52·6 (29·6, 75·7)
38·9 (15·7, 62·1)
48·0 (28·0, 68·0)
62·5 (26·6, 98·4)
41·7 (12·5, 70·8)
50·0 (26·2, 73·8)
52·9 (28·5, 77·4)
40·0 (18·0, 62·0)
Objective response rate (95% CI)
0 10 20 30 40 50 60 70 80 90 100
ORR (%)
Fig 4. Overall response rate (ORR) at end of
cycle 6 CHOP-O induction according to sub-
groups. The size of grey box is equivalent to
patient number. Diamonds indicate the objec-
tive response rate value for each specific sub-
group and the horizontal lines indicate the
95% confidence interval for that subgroup. IPI,
International Prognostic Index; ABC, activated
B-cell type; GCB, germinal centre B cell type;
95% CI, 95% confidence interval.
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Richter transformation with a high sensitivity (91%) and a
high negative predictive value (97%) (Bruzzi et al, 2006;,
Papajık et al, 2014). This is confirmed by our data showing
that the lowest SUVmax was 585. EBV detected by staining
for LMP-1 or by in situ hybridization of EBER transcripts,
has been variably reported (0–15%) in RS (Rossi et al, 2008,
2011; Parikh et al, 2013). We noted only two cases of EBV
expression in the DLBCL FFPE tissue (7%) and neither of
these 2 cases were heavily pre-treated. This data suggests a
limited role for EBV in the pathogenesis of RS overall.
Unfortunately, only limited numbers of paired samples of
sufficient DNA quality were available, but our results showed
a lower incidence of clonally unrelated cases than previously
described (Rossi et al, 2011). Compared to these retrospec-
tive studies, our cohort was biased in the sense that only
patients fit enough to receive combination chemo-immu-
notherapy were recruited into the study.
In conclusion, CHOP-O demonstrates an ORR of 46% at
the end of induction and a median PFS of just over
6 months. The CHOP-OR study demonstrates the feasibility
of undertaking clinical trials in this rare and complex patient
group. Importantly, it clearly establishes the modest efficacy
and short response duration of CHOP with induction and
maintenance ofatumumab in newly diagnosed RS. Although
not compared in a prospective randomized clinical trial, we
were not able to demonstrate a clear improvement in out-
come compared to patients treated with CHOP-R in other
phase II trials’ although the regimen studied is probably
non-inferior to CHOP-R. Our data therefore confirm that
standard immunochemotherapy for bona fide unselected RS
is inadequate.
It is encouraging that novel agents are being investigated
in RS. The second generation Bruton Tyrosine Kinase (BTK)
inhibitor ACP196 (NCT02029443), the Exportin 1 (XPO1)
inhibitor selinexor (NCT02138786), PD1 checkpoint inhibi-
tors (NCT02332980) and the BCL2 targeted DNA inhibitor
oligonucleotide PNT2258 (NCT02378038) are all currently in
early phase clinical trials. It is the authors’ hope that the
results of our relatively large national trial will promote fur-
ther national and international collaborative efforts to inves-
tigate novel treatments for RS to improve outcomes for these
patients.
Table II. Grade 3-4 adverse events and relationship to CHOP and/or ofatumumab
AE category and term
AE (SAE) unrelated
or unlikely to be
related to CHOP
or Ofatumumab
AE (SAE) possibly,
probably or almost
certainly related to
CHOP or Ofatumumab Total AE (SAE)
Blood and lymphatic
AnaemiaNeutropenia 2 (2) 3 (1) 5 (3)
Thrombocytopenia 0 11 (6) 11 (6)
Febrile Neutropenia 0 2 (0) 2 (0)
1 (1) 13 (7) 14 (8)
Gastrointestinal
Abdominal pain 1 (1) 0 1 (1)
Vomiting 0 1 (0) 1 (0)
Other 3 (2) 2 (2) 5 (4)
General disorders
Fatigue 1 (1) 0 1 (1)
Fever 0 4 (2) 4 (2)
Infusion related reaction 1 (0) 1 (1) 2 (1)
Malaise 1 (1) 0 1 (1)
Infections and infestations
Pneumonia 4 (3) 3 (1) 7 (4)
Sepsis 2 (1) 7 (7) 7 (7)
Other 2 (1) 6 (5) 8 (6)
Respiratory; thoracic and mediastinal
Aspiration 1 (1) 0 1 (1)
Bronchiectasis 0 1 (0) 1 (0)
Pleural effusion 1 (1) 0 1 (1)
Skin and subcutaneous tissue
Hyperhidrosis 0 1 (0) 1 (0)
Rash 0 2 (0) 2 (0)
Urticaria 0 1 (0) 1 (0)
Other 6 (3) 2 (0) 8 (3)
Total Grade 3 or Grade 4 AEs (SAEs) 25 (18) 60 (32) 85 (50)
AE, adverse event; SAE, serious adverse event; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone.
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Source of funding
The study is sponsored by the University of Oxford, endorsed
by CTAAC and was adopted into the NIHR portfolio. Sites
were able to access network (CLRN/NCRN) support.
GlaxoSmithKline (GSK) provided Ofatumumab free of charge
for use in the trial and additional research grant funding.
Ethical approval
Obtained from the National Research Ethics Service
(NRES) Committee South Central – Oxford A. REC refer-
ence number: 10/H0604/85. UK CLL BioBank has ethical
approval to collect samples from all NCRN associated clin-
ical studies.
Table III. Management of patients fit for ongoing treatment at relapse
Patient
Number of CHOP-O
cycles / maintenance Post CHOP-O therapy Patient status
Time from salvage
to death (d) Cause of death
Platinum-based salvage treatment
1 1 CHOP-O then PD 2 cycles R-DHAP Dead 76 PD
2 4 CHOP-O then PD 2 cycles DHAP to
PR then IFRT to CR;
consolidated with FMC
Allogenic SCT. Died in
remission (viral pneumonitis
complicating GVHD therapy).
Dead 692 PD
3 4 CHOP-O then PD 2 cycles R-ICE Dead 144 PD
4 6 CHOP-O then PD 1 cycle R-ESHAP Dead 57 PD
5 6 CHOP-O, progressed
on maintenance O
1 cycle R-ICE - >1 cycle
GEM-P- > 1 cycle FMD.
No response.
Dead 106 PD
6 4 CHOP-O then PD 1 cycle R-ICE then
1 cycle R-ESHAP.
No response.
Dead 37 PD
7 6 CHOP-O, progressed
on maintenance O
3 cycles R-ICE ->PD.
Selinexor clinical trial
->PD. Started ACP196 trial.
Alive with PD
(22 June 2015)
Alive at 35 d N/A
Other salvage treatment
8 6 CHOP-O, progressed
on maintenance O
Radiotherapy, autologous
CD19-specific T-cells
with pre-conditioning
and IL2 on phase 1 trial,
then ibrutinib
Alive
(24 April 2015)
Alive at 646 d N/A
9 4 CHOP-O then PD Alemtuzumab given pre-SCT;
however halted due to
CMV reactivation,
subsequent PD
Dead 66 PD
10 5 cycles of CHOP-O.
Stopped due to
O intolerance
Repeat BMAT: 90% CLL
with no evidence of RS.
Known TP53 deletion: pulse
of dexamethasone then
alemtuzumab and HDMP
Dead 145 Traumatic SDH
11 6 CHOP-O,
progressed on
maintenance O
1 cycle IVE to date Alive
(27 April 2015)
Alive at 24 d N/A
CHOP-O, cyclophosphamide, doxorubicin, vincristine, prednisolone, ofatumumab; O, ofatumumab (R)-DHAP, (rituximab) dexamethasone, high
dose cytarabine, cisplatin; R-ICE, rituximab, ifosfamide, carboplatin, etoposide; R-ESHAP, rituximab, etoposide, high dose cytarabine, methyl-
prednisolone, cisplatin; GEM-P, gemcitabine, cisplatin, methylprednisolone; BEAM, BCNU (carmustine), etoposide, cytarabine, melphalan; FMD,
fludarabine, mitoxantrone, dexamethasone, ACP196, acalabrutinib; IL2, interleukin 2; SCT, stem cell transplantation; IVE, ifosfamide, epirubicin,
etoposide; FMC, fludarabine, melphalan, alemtuzumab; HDMP: high dose methylprednisolone; CR, complete remission; SD, stable disease; PD,
progressive disease; CMV, cytomegalovirus; SDH, subdural haemorrhage; BMAT: bone marrow aspirate and trephine biopsy; GVHD, graft-ver-
sus-host disease; IFRT, involved field radiotherapy.
T. A. Eyre et al
52 ª 2016 John Wiley & Sons Ltd
British Journal of Haematology, 2016, 175, 43–54
Acknowledgements
This work was supported by the Oxford Partnership Com-
prehensive Biomedical Research Centre with funding from
the Department of Health National Institute of Health
Research (NIHR) Biomedical Research Centre funding
scheme. The views expressed in this publication are those of
the authors and not necessarily those of the Department of
Health. The CHOP-OR study group acknowledges the sup-
port of the National Institute for Health Research, through
the National Cancer Research Network. TE is funded by the
Julian Starmer-Smith lymphoma fund. GC acknowledges
support by the National Institute for Health Research
(NIHR) Oxford Biomedical Research Centre Programme.
The views expressed are those of the authors and not neces-
sarily those of the funding bodies.
Author contributions
A.S., P.H. and A.P. made substantial contributions to con-
ception and design. A.B., S.D., G.F., C.F., J.G., C.H., H.M.C.,
J.M., P.H., A.P., G.C. and A.S. provided patients for the
study. T.J.L., G.C., T.E., R.C., C.R., B.S. and L.B. were
involved in collection and assembly of data. T.E., A.S., R.C.,
C.R., S.L., E.S. and A.W. were involved in data analysis and
interpretation. T.E. drafted the manuscript. All authors were
involved in critically revising the manuscript and the final
approval.
Conflict of Interest
A.S., T.E., A.B., A.P., G.F., S.D. have received consultancy
honoraria from GSK. A.P. and A.S. has received research
funding from GSK. P.H., G.F. and S.D. have received speaker
fees for GSK.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Fig S1. Summary of Recruitment.
Fig S2. Results of PET-CT.
Fig S3. Additional survival analyses according to defined
subgroups.
References
Barth, M.J., Hernandez-Ilizaliturri, F.J., Mavis, C.,
Tsai, P.-C., Gibbs, J.F., Deeb, G. & Czuczman,
M.S. (2012) Ofatumumab demonstrates activity
against rituximab-sensitive and -resistant cell
lines, lymphoma xenografts and primary tumour
cells from patients with B-cell lymphoma. Br J
Haematol, 156, 490–498.
Bockorny, B., Codreanu, I. & Dasanu, C.A. (2012)
Hodgkin lymphoma as Richter transformation
in chronic lymphocytic leukaemia: a retrospec-
tive analysis of world literature. Br J Haematol,
156, 50–66.
Bruzzi, J.F., Macapinlac, H., Tsimberidou, A.M.,
Truong, M.T., Keating, M.J., Marom, E.M. &
Munden, R.F. (2006) Detection of Richter’s
transformation of chronic lymphocytic leukemia
by PET/CT. J Nucl Med, 47, 1267–1273.
Campbell, M.J., Zelenetz, A.D., Levy, S. & Levy, R.
(1992) Use of family specific leader region pri-
mers for PCR amplification of the human heavy
chain variable region gene repertoire. Mol
Immunol, 29, 193–203.
Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne,
R.D., Specht, L., Horning, S.J., Coiffier, B.,
Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen,
S.T., Stroobants, S., Lister, T.A., Hoppe, R.T.,
Dreyling, M., Tobinai, K., Vose, J.M., Connors,
J.M., Federico, M. & Diehl, V. (2007) Revised
response criteria for malignant lymphoma. J
Clin Oncol, 25, 579–586.
Chigrinova, E., Rinaldi, A., Kwee, I., Rossi, D.,
Rancoita, P.M.V., Strefford, J.C., Oscier, D.,
Stamatopoulos, K., Papadaki, T., Berger, F.,
Young, K.H., Murray, F., Rosenquist, R.,
Greiner, T.C., Chan, W.C., Orlandi, E.M.,
Lucioni, M., Marasca, R., Inghirami, G., Ladetto,
M., Forconi, F., Cogliatti, S., Votavova, H.,
Swerdlow, S.H., Stilgenbauer, S., Piris, M.A.,
Matolcsy, A., Spagnolo, D., Nikitin, E., Zamo,
A., Gattei, V., Bhagat, G., Ott, G., Zucca, E.,
Gaidano, G. & Bertoni, F. (2013) Two main
genetic pathways lead to the transformation of
chronic lymphocytic leukemia to Richter syn-
drome. Blood, 122, 2673–2682.
Coiffier, B., Lepage, E., Briere, J., Herbrecht, R.,
Tilly, H., Bouabdallah, R., Morel, P., Van Den
Neste, E., Salles, G., Gaulard, P., Reyes, F., Leder-
lin, P. & Gisselbrecht, C. (2002) CHOP
chemotherapy plus rituximab compared with
CHOP alone in elderly patients with diffuse large-
B-cell lymphoma. N Engl J Med, 346, 235–242.
Dabaja, B.S., O’Brien, S.M., Kantarjian, H.M.,
Cortes, J.E., Thomas, D.A., Albitar, M., Schlette,
E.S., Faderl, S., Sarris, A., Keating, M.J. & Giles,
F.J. (2001) Fractionated cyclophosphamide, vin-
cristine, liposomal daunorubicin (daunoXome),
and dexamethasone (hyperCVXD) regimen in
Richter’s syndrome. Leuk Lymphoma, 42, 329–
337.
Eyre, T.A., Clifford, R., Roberts, C., Boyle, L.,
Francis, A., Schuh, A. & Dutton, S.J. (2015) Sin-
gle arm NCRI phase II study of CHOP in com-
bination with Ofatumumab in induction and
maintenance for patients with newly diagnosed
Richter’s syndrome. BMC Cancer, 15, 52.
Falchi, L., Keating, M.J., Marom, E.M., Truong,
M.T., Schlette, E.J., Sargent, R.L., Trinh, L.,
Wang, X., Smith, S.C., Jain, N., Estrov, Z.,
O’Brien, S., Wierda, W.G., Lerner, S. & Ferra-
joli, A. (2014) Correlation between FDG/PET,
histology, characteristics, and survival in 332
patients with chronic lymphoid leukemia. Blood,
123, 2783–2790.
Green, T.M., Young, K.H., Visco, C., Xu-Monette,
Z.Y., Orazi, A., Go, R.S., Nielsen, O., Gadeberg,
O.V., Mourits-Andersen, T., Frederiksen, M.,
Pedersen, L.M. & Moller, M.B. (2012) Immuno-
histochemical double-hit score is a strong pre-
dictor of outcome in patients with diffuse large
B-cell lymphoma treated with rituximab plus
cyclophosphamide, doxorubicin, vincristine, and
prednisone. J Clin Oncol, 30, 3460–3467.
Hamblin, T.J., Davis, Z., Gardiner, A., Oscier,
D.G. & Stevenson, F.K. (1999) Unmutated Ig V
(H) genes are associated with a more aggressive
form of chronic lymphocytic leukemia. Blood,
94, 1848–1854.
Hans, C.P., Weisenburger, D.D., Greiner, T.C.,
Gascoyne, R.D., Delabie, J., Ott, G., M€uller-Her-
melink, H.K., Campo, E., Braziel, R.M., Jaffe,
E.S., Pan, Z., Farinha, P., Smith, L.M., Falini, B.,
Banham, A.H., Rosenwald, A., Staudt, L.M.,
Connors, J.M., Armitage, J.O. & Chan, W.C.
(2004) Confirmation of the molecular classifica-
tion of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microar-
ray. Blood, 103, 275–282.
Langerbeins, P., Busch, R., Anheier, N., D€urig, J.,
Bergmann, M., Goebeler, M.-E., Hurtz, H.-J.,
Stauch, M.B., Stilgenbauer, S., D€ohner, H., Fink,
A.-M., Cramer, P., Fischer, K., Wendtner, C.-
M., Hallek, M. & Eichhorst, B. (2014) Poor effi-
cacy and tolerability of R-CHOP in relapsed/re-
fractory chronic lymphocytic leukemia and
Richter transformation. Am J Hematol, 89, 239–
243.
CHOP with Ofatumumab in Richter Syndrome
ª 2016 John Wiley & Sons Ltd 53
British Journal of Haematology, 2016, 175, 43–54
Morton, L.M., Wang, S.S., Devesa, S.S., Hartge, P.,
Weisenburger, D.D. & Linet, M.S. (2006) Lym-
phoma incidence patterns by WHO subtype in
the United States, 1992-2001. Blood, 107, 265–
276.
Papajık, T., Myslivecek, M., Urbanova, R.,
Buriankova, E., Kapitanova, Z., Prochazka, V.,
Turcsanyi, P., Formanek, R., Henzlova, L.,
Flodr, P., Jarosova, M. & Indrak, K. (2014) 2-
[18F]fluoro-2-deoxy-D-glucose positron emis-
sion tomography/computed tomography exami-
nation in patients with chronic lymphocytic
leukemia may reveal Richter transformation.
Leuk Lymphoma., 55, 314–319.
Parikh, SA, Rabe, K.G., Call, T.G., Zent, C.S.,
Habermann, T.M., Ding, W., Leis, J.F., Schwa-
ger, S.M., Hanson, C. a, Macon, W.R., Kay,
N.E., Slager, S.L. & Shanafelt, T.D. (2013) Dif-
fuse large B-cell lymphoma (Richter syndrome)
in patients with chronic lymphocytic leukaemia
(CLL): a cohort study of newly diagnosed
patients. Br J Haematol, 162, 774–782.
Rogers, K.A., Salem, G., Stephens, D.M., Andritsos,
L.A., Awan, F.T., Byrd, J.C., Flynn, J.M., Mad-
docks, K.J., Huang, Y., Ruppert, A.S. & Jones,
J.A. (2015) A single-institution retrospective
cohort study of patients treated with R-EPOCH
for Richter’s transformation of chronic lympho-
cytic leukemia. Blood, 126, 2951.
Rossi, D., Cerri, M., Capello, D., Deambrogi, C.,
Rossi, F.M., Zucchetto, A., De Paoli, L., Cresta,
S., Rasi, S., Spina, V., Franceschetti, S., Lunghi,
M., Vendramin, C., Bomben, R., Ramponi, A.,
Monga, G., Conconi, A., Magnani, C., Gattei, V.
& Gaidano, G. (2008) Biological and clinical risk
factors of chronic lymphocytic leukaemia trans-
formation to Richter syndrome. Br J Haematol,
142, 202–215.
Rossi, D., Spina, V., Deambrogi, C., Rasi, S., Lau-
renti, L., Stamatopoulos, K., Arcaini, L., Lucioni,
M., Rocque, G.B., Xu-Monette, Z.Y., Visco, C.,
Chang, J., Chigrinova, E., Forconi, F., Marasca,
R., Besson, C., Papadaki, T., Paulli, M., Larocca,
L.M., Pileri, S.A., Gattei, V., Bertoni, F., Foa, R.,
Young, K.H. & Gaidano, G. (2011) The genetics
of Richter syndrome reveals disease heterogene-
ity and predicts survival after transformation.
Blood, 117, 3391–3401.
Tadmor, T., Shvidel, L., Bairey, O., Goldschmidt,
N., Ruchlemer, R., Fineman, R., Rahimi-Levene,
N., Herishanu, Y., Yuklea, M., Arad, A., Aviv, A.
& Polliack, A. (2014) Richter’s transformation
to diffuse large B-cell lymphoma: a retrospective
study reporting clinical data, outcome, and the
benefit of adding rituximab to chemotherapy,
from the Israeli CLL Study Group. Am J Hema-
tol, 89, 218–222.
Teeling, J.L., Mackus, W.J.M., Wiegman, L.J.J.M.,
van den Brakel, J.H.N., Beers, S.A., French, R.R.,
van Meerten, T., Ebeling, S., Vink, T., Slootstra,
J.W., Parren, P.W.H.I., Glennie, M.J. & van de
Winkel, J.G.J. (2006) The biological activity of
human CD20 monoclonal antibodies is linked
to unique epitopes on CD20. J Immunol, 177,
362–371.
Tsimberidou, A.M., O’Brien, S.M., Cortes, J.E.,
Faderl, S., Andreeff, M., Kantarjian, H.M., Keat-
ing, M.J. & Giles, F.J. (2002) Phase II study of
fludarabine, cytarabine (Ara-C), cyclophos-
phamide, cisplatin and GM-CSF (FACPGM) in
patients with Richter’s syndrome or refractory
lymphoproliferative disorders. Leuk Lymphoma,
43, 767–772.
Tsimberidou, A.M., Kantarjian, H.M., Cortes, J.,
Thomas, D.A., Faderl, S., Garcia-Manero, G.,
Verstovsek, S., Ferrajoli, A., Wierda, W., Alvar-
ado, Y., O’Brien, S.M., Albitar, M., Keating, M.J.
& Giles, F.J. (2003) Fractionated cyclophos-
phamide, vincristine, liposomal daunorubicin,
and dexamethasone plus rituximab and
granulocyte-macrophage-colony stimulating fac-
tor (GM-CSF) alternating with methotrexate
and cytarabine plus rituximab and GM-CSF in
patients with Rich. Cancer, 97, 1711–1720.
Tsimberidou, A.-M., O’Brien, S., Khouri, I., Giles,
F.J., Kantarjian, H.M., Champlin, R., Wen, S.,
Do, K.-A., Smith, S.C., Lerner, S., Freireich, E.J.
& Keating, M.J. (2006) Clinical outcomes and
prognostic factors in patients with Richter’s syn-
drome treated with chemotherapy or chemoim-
munotherapy with or without stem-cell
transplantation. J Clin Oncol, 24, 2343–2351.
Tsimberidou, A.M., Wierda, W.G., Plunkett, W.,
Kurzrock, R., O’Brien, S., Wen, S., Ferrajoli, A.,
Ravandi-Kashani, F., Garcia-Manero, G., Estrov,
Z., Kipps, T.J., Brown, J.R., Fiorentino, A., Ler-
ner, S., Kantarjian, H.M. & Keating, M.J. (2008)
Phase I-II study of oxaliplatin, fludarabine,
cytarabine, and rituximab combination therapy
in patients with Richter’s syndrome or fludara-
bine-refractory chronic lymphocytic leukemia. J
Clin Oncol, 26, 196–203.
Tsimberidou, A.M., Wierda, W.G., Wen, S., Plun-
kett, W., O’Brien, S., Kipps, T.J., Jones, J.A.,
Badoux, X., Kantarjian, H. & Keating, M.J.
(2013) Phase I-II clinical trial of oxaliplatin, flu-
darabine, cytarabine, and rituximab therapy in
aggressive relapsed/refractory chronic lympho-
cytic leukemia or Richter syndrome. Clin Lym-
phoma Myeloma Leuk, 13, 568–574.
Wierda, W.G., Kipps, T.J., Mayer, J., Stilgenbauer,
S., Williams, C.D., Hellmann, A., Robak, T.,
Furman, R.R., Hillmen, P., Trneny, M., Dyer,
M.J.S., Padmanabhan, S., Piotrowska, M.,
Kozak, T., Chan, G., Davis, R., Losic, N., Wilms,
J., Russell, C.A. & Osterborg, A. (2010) Ofatu-
mumab as single-agent CD20 immunotherapy
in fludarabine-refractory chronic lymphocytic
leukemia. J Clin Oncol, 28, 1749–1755.
54 ª 2016 John Wiley & Sons Ltd
British Journal of Haematology, 2016, 175, 43–54
T. A. Eyre et al
